Biomedicine & Pharmacotherapy (Jun 2023)

New therapy for pancreatic cancer based on extracellular vesicles

  • Salomé Araujo-Abad,
  • Antonio Manresa-Manresa,
  • Enrique Rodríguez-Cañas,
  • María Fuentes- Baile,
  • Pilar García-Morales,
  • Ricardo Mallavia,
  • Miguel Saceda,
  • Camino de Juan Romero

Journal volume & issue
Vol. 162
p. 114657

Abstract

Read online

Pancreatic Ductal Adenocarcinoma (PDAC), is the most common aggressive cancer of the pancreas. The standard care of PDAC includes tumor resection and chemotherapy, but the lack of early diagnosis and the limited response to the treatment worsens the patient’s condition. In order to improve the efficiency of chemotherapy, we look for more efficient systems of drug delivery. We isolated and fully characterized small Extracellular Vesicles (EVs) from the RWP-1 cell line. Our study indicates that the direct incubation method was the most efficient loading protocol and that a minimum total amount of drug triggers an effect on tumor cells. Therefore, we loaded the small EVs with two chemotherapeutic drugs (Temozolomide and EPZ015666) by direct incubation method and the amount of drug loaded was measured by high-performance liquid chromatography (HPLC). Finally, we tested their antiproliferative effect on different cancer cell lines. Moreover, the system is highly dependent on the drug structure and therefore RWP-1 small EVsTMZ were more efficient than RWP-1 small EVsEPZ015666. RWP-1 derived small EVs represent a promising drug delivery tool that can be further investigated in preclinical studies and its combination with PRMT5 inhibitor can be potentially developed in clinical trials for the treatment of PDAC.

Keywords